- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00441168
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
February 20, 2014 updated by: Janssen-Cilag International NV
A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade When Added to Adriamycin-Dexamethasone Treatment Versus Vincristine-Adriamycin-Dexamethasone Standard Treatment in Subjects With Multiple Myeloma Who Are Refractory to or Have Relapsed After Primary Therapy for Multiple Myeloma
The purpose of this research study is to test the safety and effectiveness of replacing vincristine with a drug called bortezomib (also known as "Velcade"or PS341) in the standard therapy vincristine, doxorubicin (not limited to, but formerly referred to under the tradename Adriamycin) and dexamethasone (VAD) in patients with multiple myeloma.
Multiple Myeloma is the second most common cancer of the blood.
Bortezomib is the first approved cancer treatment in a new class of medicines called proteasome inhibitors.
It disrupts the cell cycle of the cell, affecting numerous biologic pathways, including those related to growth and survival of cancer cells.
The treatment will be used as second line treatment, which means either the disease has returned after a period of improvement (relapse) or the disease did not respond to the initial treatment (refractory).
Patients will receive either bortezomib (PS341), doxorubicin (Adriamycin) and dexamethasone (PAD) or the VAD standard therapy.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Bortezomib, has been approved for use in patients with multiple myeloma, who have already received at least one prior treatment and whose disease is worsening on their last treatment and who have already undergone or are unsuitable for bone marrow transplantation.
Bortezomib has significant activity in patients with relapsed multiple myeloma, its efficacy is increased with the addition of dexamethasone and it demonstrates synergy with doxorubicin.
The VAD combination has been widely used in multiple myeloma and has demonstrated to be effective in relapsed patients.
Based on previous trial results, it is hoped that bortezomib, in replacing vincristine in the VAD standard therapy, can improve the response to treatment of patients with multiple myeloma, with manageable side effects.
This is an international, multicentre, randomised, open-label, parallel group study.
About 212 patients will take part in the study.
Patients will be treated with either bortezomib (PS-341), Adriamycin and Dexamethasone (PAD) or Vincristine, Adriamycin and Dexamethasone (VAD).
There will be an initial 14 day screening period to evaluate if the patient is suitable for the study.
After screening, eligible patients will be randomised to receive either PAD or VAD.
Patients will receive therapy for up to 8 treatment cycles of 28 days each.
After the treatment period, there will be a long-term follow-up period with monthly visits until disease progression or relapse.
Thereafter follow-up will be continued by at least a phone call every other month.
This long-term follow-up period will be performed for all patients until the last patient was treated and followed up for 1 year.
Response to treatment will be assessed according to the European group for blood and marrow transplant criteria (EBMT).
Disease burden will be monitored by measuring M-protein concentration in serum and in urine every 4 weeks until disease progression or relapse.
Thereafter follow-up for survival will be continued every other month by at least a phone call.
Safety will be assessed by monitoring of adverse events (AEs), vital signs, physical examination and clinical laboratory tests.
Treatment with PAD or VAD will be for up to 8 cycles of 28 days each.
Treatment beyond 6 cycles will be discussed on individual basis.
Proposed dosages are: bortezomib 1.3 mg/m² intravenous (IV) bolus on Days 1, 4, 8, and 11; vincristine 0.4mg IV push on Days 1 to 4; doxorubicin 9mg/m² IV push on Days 1 to 4; dexamethasone in 1st cycle 40 mg daily on Days 1 to 4, 9 to 12 and 17 to 20, orally (or equivalent parenteral dose) and on subsequent cycles as 40 mg daily on Days 1 to 4 and 17 to 20 only.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Zagreb, Croatia
-
-
-
-
-
Leer, Germany
-
Velbert, Germany
-
-
-
-
-
Debrecen, Hungary
-
-
-
-
-
Kaunas, Lithuania
-
Klaipeda, Lithuania
-
Vilnius, Lithuania
-
-
-
-
-
Bialystok, Poland
-
Gdansk, Poland
-
Poznan, Poland
-
-
-
-
-
Moscow, Russian Federation
-
Samara, Russian Federation
-
St Petersburg, Russian Federation
-
-
-
-
-
Ankara, Turkey
-
Bursa, Turkey
-
Eskisehir, Turkey
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Relapsed or refractory multiple myeloma following 1 previous line of therapy and, is scheduled by the investigator to be treated with vincristine, adriamycin and dexamethasone standard therapy
- measurable secretory multiple myeloma based on defined criteria
- Karnofsky performance status of >or = 60%
- fulfils defined laboratory requirements within 14 days before baseline
- if female, the patient is either postmenopausal or surgically sterilised or willing to use an acceptable method of birth control for defined period of time
- if male, the patient agrees to use an acceptable barrier method for contraception for a defined period of time.
Exclusion Criteria:
- More than one previous line of therapy for multiple myeloma
- use of bortezomib in the previous line of therapy and/or received bortezomib in a previous trial
- known allergy or hypersensitivity to bortezomib, boron or mannitol
- peripheral neuropathy or neuropathic pain of grade 2 or higher
- myocardial infarction within 6 months of enrollment or had New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: VAD Treatment
vincristine in combination with adriamycin and dexamethasone
|
adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
vincristine: 0.4mg IV push on days 1 to 4
|
Experimental: PAD Treatment
bortezomib in combination with adriamycin and dexamethasone
|
adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Confirmed Disease Response
Time Frame: every 28 days during treatment period for up to 6 to 8 cycles
|
The primary efficacy analysis was based on the best response obtained during the treatment period according to the European Group for Blood and Marrow Transplantation (EBMT) criteria as assessed by the investigator.
The best confirmed response was defined as 2 separate and consecutive evaluations of response, at least 6 weeks apart (for progressive disease [PD], 1 to 3 weeks apart).
The ordering of the responses was: complete response (CR), partial response (PR), minimal response (MR), no change (NC) and PD.
CR was the best response and the poorest response was PD.
|
every 28 days during treatment period for up to 6 to 8 cycles
|
Best Reported Disease Response
Time Frame: every 28 days during treatment period for up to 6 to 8 cycles
|
The primary efficacy analysis was based on the best response obtained during the treatment period according to the EBMT criteria as assessed by the investigator.
The ordering of the responses was: CR, PR, MR, NC and PD.
CR was the best response and the poorest response was PD.
|
every 28 days during treatment period for up to 6 to 8 cycles
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR)
Time Frame: every 28 days during treatment period for up to 6 to 8 cycles
|
DOR was defined as the duration from the date of the best confirmed response for subjects who achieved CR or PR to the date of first documented evidence of PD (or relapse for subjects who experienced CR) over the duration of the study.
DOR = ([Date of PD or date of censoring - Date of best response]+1)/30.44.
|
every 28 days during treatment period for up to 6 to 8 cycles
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
January 1, 2008
Study Completion (Actual)
January 1, 2008
Study Registration Dates
First Submitted
February 27, 2007
First Submitted That Met QC Criteria
February 27, 2007
First Posted (Estimate)
February 28, 2007
Study Record Updates
Last Update Posted (Estimate)
March 21, 2014
Last Update Submitted That Met QC Criteria
February 20, 2014
Last Verified
February 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Dexamethasone
- Bortezomib
- Doxorubicin
- Liposomal doxorubicin
- Vincristine
Other Study ID Numbers
- CR011065
- 26866138MMY2038 (Other Identifier: Janssen-Cilag International NV)
- 2006-001709-27 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on adriamycin
-
M.D. Anderson Cancer CenterWithdrawnMalignant Neoplasms of Mesothelial and Soft Tissue | Rhabdomyosarcoma, Pelvic | Rhabdomyosarcoma, Abdominal
-
Basilea PharmaceuticaCompletedHand DermatosesGermany
-
Basilea PharmaceuticaCompletedHand DermatosesGermany
-
M.D. Anderson Cancer CenterAmgenCompletedSarcomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Completed
-
OHSU Knight Cancer InstituteNovartis Pharmaceuticals; Oregon Health and Science UniversityCompletedStage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Locally Advanced Leiomyosarcoma | Unresectable Leiomyosarcoma | Myxofibrosarcoma | Metastatic Malignant Peripheral Nerve Sheath Tumor | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Unresectable... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Dermatofibrosarcoma Protuberans | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Adult Angiosarcoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
The Netherlands Cancer InstituteDaiichi Sankyo, Inc.Not yet recruitingEGFR Gene Mutation | Non-Small Cell Lung Carcinoma | Advanced Non-Small Cell Squamous Lung Cancer
-
University of NebraskaNational Cancer Institute (NCI)CompletedRecurrent Small Cell Lung CarcinomaUnited States